Skip to content

Inspection Record

Regeneron Pharmaceuticals, Inc. — FDA 483 Findings

US FDAInspected 2015-07-10Published 2024-01-17 3 findingsMaterial and supplier controlLaboratory and QC controlsComplaint and recall handling

View the regulator's official source The source document is always the basis for judgement.

Findings

1Material and supplier control

Review of the firm’s manual log for SCARs (Supplier Corrective Action Requests) which was stated to betheoriginal, GMP document for tracicing these events found numerous entries for the past two years which were not closed out.

2Laboratory and QC controls

There are no security measures employed in the issuance ofworksheets in the raw material testing laboratory located in building gay Inspection found that it is possible to print additiona) uncontrolled blank worksheets.

3Complaint and recall handling

The role ofthe “reimbursement vendor” in providing information related to quality compiaints and the documentation in the complaint file of communications with that agent is not adequately addressed in the applicable complaint handling procedure.

A record as of the US FDA document published on 2024-01-17. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Other records for this company

Regeneron Pharmaceuticals, Inc. findings history — including this company's other documentsAll US FDA findings US FDA documents, 2024 Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.